Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Schwab

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Investigation|January 2, 2025
A single-cell compendium of human cerebrospinal fluid identifies disease-associated immune cell populationsClaudia Cantoni, Roman A Smirnov, Maria Firulyova, et al.
Brain : a Journal of Neurology|December 1, 2021
Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunityMarie Liebmann, Lisanne Korn, Claudia Janoschka, et al.
Brain : a Journal of Neurology|April 13, 2021
Classification of neurological diseases using multi-dimensional CSF analysisCatharina C Gross, Andreas Schulte-Mecklenbeck, Lohith Madireddy, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease reboundClaudia Janoschka, Maren Lindner, Nils Koppers, et al.
Therapeutic Advances in Neurological Disorders|December 12, 2023
Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment responseValerie E Teschner, Ann-Katrin Fleck, Carolin Walter, et al.
Brain : a Journal of Neurology|June 6, 2022
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunityTobias Ruck, Sumanta Barman, Andreas Schulte-Mecklenbeck, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2015
PML risk stratification using anti-JCV antibody index and L-selectinNicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.
The Journal of Experimental Medicine|September 1, 2022
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosisTilman Schneider-Hohendorf, Lisa Ann Gerdes, Béatrice Pignolet, et al.
Frontiers in Neurology|January 2, 2023
Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapiesEli Hatchwell, Edward B Smith, Shapour Jalilzadeh, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Investigation|January 2, 2025
A single-cell compendium of human cerebrospinal fluid identifies disease-associated immune cell populationsClaudia Cantoni, Roman A Smirnov, Maria Firulyova, et al.
Brain : a Journal of Neurology|December 1, 2021
Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunityMarie Liebmann, Lisanne Korn, Claudia Janoschka, et al.
Brain : a Journal of Neurology|April 13, 2021
Classification of neurological diseases using multi-dimensional CSF analysisCatharina C Gross, Andreas Schulte-Mecklenbeck, Lohith Madireddy, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease reboundClaudia Janoschka, Maren Lindner, Nils Koppers, et al.
Therapeutic Advances in Neurological Disorders|December 12, 2023
Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment responseValerie E Teschner, Ann-Katrin Fleck, Carolin Walter, et al.
Brain : a Journal of Neurology|June 6, 2022
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunityTobias Ruck, Sumanta Barman, Andreas Schulte-Mecklenbeck, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2015
PML risk stratification using anti-JCV antibody index and L-selectinNicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet, et al.
The Journal of Experimental Medicine|September 1, 2022
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosisTilman Schneider-Hohendorf, Lisa Ann Gerdes, Béatrice Pignolet, et al.
Frontiers in Neurology|January 2, 2023
Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapiesEli Hatchwell, Edward B Smith, Shapour Jalilzadeh, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Pageof 8